International Liver Congress (ILC) 2021

Digital 23 June 2021 - 26 June 2021

Tenofovir alafenamide may prevent HBV mother-to-child transmission

19 Aug 2021 bởi

Tenofovir alafenamide (TAF), administered during the second or third trimester of pregnancy, may prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection, according to two studies presented as posters at ILC 2021.

Tenofovir alafenamide may prevent HBV mother-to-child transmission

19 Aug 2021

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

06 Aug 2021 bởi

The addition of amoxicillin/clavulanate to prednisolone does not extend survival among patients with severe alcoholic hepatitis, though it may reduce infection risk, according to a French study presented at ILC 2021.

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

06 Aug 2021

Tenofovir tied to lower risk of severe COVID-19 in HBV patients

18 Jul 2021 bởi

Patients with chronic hepatitis B virus (HBV) infection who were treated with tenofovir had a lower risk of developing severe COVID-19 illness than those treated with entecavir, according to a study presented at the EASL International Liver Congress (ILC) 2021.

Tenofovir tied to lower risk of severe COVID-19 in HBV patients

18 Jul 2021

Phase II trial updates underpin benefit of efruxifermin for NASH

16 Jul 2021 bởi

In individuals with biopsy-confirmed nonalcoholic steatohepatitis (NASH) with fibrosis, the reductions in liver fat content (LFC) with efruxifermin correlated with improvements in markers of liver injury, fibrosis, metabolic parameters, and histologic features, according to updates from the phase IIa BALANCED study presented at ILC 2021.

Phase II trial updates underpin benefit of efruxifermin for NASH

16 Jul 2021

New liver dialysis device – how safe in cirrhosis?

15 Jul 2021 bởi

A novel liver dialysis device appeared safe vs standard of care (SoC) in patients with acute on chronic liver failure (ACLF) in a small randomized study in Europe.

New liver dialysis device – how safe in cirrhosis?

15 Jul 2021

Phase III data support resmetirom potential for NAFLD/NASH

14 Jul 2021 bởi

In individuals with nonalcoholic fatty liver disease (NAFLD) or presumed nonalcoholic steatohepatitis (NASH), resmetirom, an investigational, once-daily, oral selective thyroid hormone receptor beta agonist, significantly improved several hepatic and cardiovascular (CV) parameters, according to the findings of the phase III MAESTRO-NAFLD1 trial presented at ILC 2021.

Phase III data support resmetirom potential for NAFLD/NASH

14 Jul 2021